Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex  >  All News

News : Economy & Forex
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies / ForexCryptocurrenciesEconomic EventsPress releases

Aspen stock rises almost 6% after half-year results forecast ahead of estimates

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2020 | 05:05am EDT
An Aspen Pharmacare logo is seen at outside company offices in Woodmead

Aspen Pharmacare Holdings Ltd's shares surged 5.7% on Monday, putting the South African drugmaker on track for its biggest one-day gain in more than two-months after it said its half-year results would likely beat estimates.

The nearly 170-year-old drug maker, with a presence in about 56 countries, said on Friday it expects to report half-year results slightly above its forecast as its manufacturing unit benefited from the restart of heparin sales to third party customers.

At 0856 GMT, shares in Aspen were 3.11% firmer at 110.88 rand, having risen as high as 113.72 rand, and on course for their biggest one-day gain since December 17.

The market also cheered Aspen for lowering its debt to about 38 billion rand ($2.53 billion) by Dec.31. The firm said its leverage ratio, which assesses the ability of a firm to meet its financial obligations, is likely to end between 3.50x and 3.60x against a covenant threshold of 4.0x, the firm added.

Aspen said assuming the net proceeds from the sale of its Japanese business to Swiss drugmaker Novartis were received on Dec.31, the leverage ratio would have been between 3.20x and 3.30x.

Investors have been concerned about Aspen's debt in the last two years after levels moved close to breaching debt covenants.

In September it said it was aiming for a leverage ratio of less than 3.0x in the medium term as it bets on positive free cash flows and a substantial decline in planned capital expenditure after the 2020 financial year.

"The forced sale of the formula business and the Japanese business seems to have saved Aspen from a rights issue," Vestact Portfolio Manager, Byron Lotter said in a note.

"I expect the share price to react positively to this news. At these levels, it seems to be a good potential turn around story."

(Reporting by Nqobile Dludla; Editing by Kirsten Donovan)

Stocks treated in this article : Aspen Pharmacare Holdings Limited, Novartis
Stocks mentioned in the article
ChangeLast1st jan.
ASPEN PHARMACARE HOLDINGS LIMITED -4.33% 91.9 End-of-day quote.-1.38%
NOVARTIS -1.20% 76 Delayed Quote.-16.30%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Economy & Forex"
07:03aDEPARTMENT OF PETROLEUM RESOURCES OF NIGERIA : DPR orders oil firms to reduce offshore workforce
PU
06:59aEXCLUSIVE : Qatar Airways says it will need state support as cash runs out
RE
06:15aCoronavirus Divides Restaurants Into Those With or Without Drive-Throughs
DJ
05:33aAICD AUSTRALIAN INSTITUTE OF DIRECTORS : backs calls for widespread wage subsidies
PU
05:28aQATAR CENTRAL BANK : Launches Mobile Payment System
PU
05:18aSwitzerland might increase 20 billion franc emergency scheme - Finance Minister
RE
05:02aEgypt's banks told to limit withdrawals, deposits
RE
04:23aSouth Africa may approach the IMF for "health funding" -Mboweni
RE
03:33aPCBS PALESTINIAN CENTRAL BUREAU OF STATISTICS : The Preliminary Results of the Palestinian Balance of Payments , Fourth Quarter, 2019
PU
02:22aOil-rich wealth funds seen shedding upto $225 billion in stocks
RE
Latest news "Economy & Forex"